Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 527

1.

Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.

Tenold M, Ravi P, Kumar M, Bowman A, Hammers H, Choueiri TK, Lara PN Jr.

Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279881.

2.

Patient-Reported Outcomes in a Phase 2 Study Comparing Atezolizumab Alone or With Bevacizumab Versus Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma.

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suarez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T.

BJU Int. 2020 Mar 31. doi: 10.1111/bju.15058. [Epub ahead of print]

PMID:
32233107
3.

Geographic Distribution of Racial Differences in Prostate Cancer Mortality.

Fletcher SA, Marchese M, Cole AP, Mahal BA, Friedlander DF, Krimphove M, Kilbridge KL, Lipsitz SR, Nguyen PL, Choueiri TK, Kibel AS, Trinh QD.

JAMA Netw Open. 2020 Mar 2;3(3):e201839. doi: 10.1001/jamanetworkopen.2020.1839.

4.

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.

Bossé D, Xie W, Lin X, Simantov R, Lalani AA, Graham J, Wells JC, Donskov F, Rini B, Beuselinck B, Alva A, Hansen A, Wood L, Soulières D, Kollmannsberger C, Patenaude F, Heng DYC, Choueiri TK, McKay RR.

JCO Glob Oncol. 2020 Feb;6:293-306. doi: 10.1200/JGO.19.00380.

5.

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.

Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC.

J Immunother Cancer. 2020 Feb;8(1). pii: e000144. doi: 10.1136/jitc-2019-000144.

6.

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Donskov F, Xie W, Overby A, Wells JC, Fraccon AP, Sacco CS, Porta C, Stukalin I, Lee JL, Koutsoukos K, Yuasa T, Davis ID, Pezaro C, Kanesvaran R, Bjarnason GA, Sim HW, Rathi N, Kollmannsberger CK, Canil CM, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2020 Feb 6. pii: S2588-9311(20)30008-0. doi: 10.1016/j.euo.2020.01.001. [Epub ahead of print]

7.

The role of site-specific therapy for cancers of unknown of primary: A meta-analysis.

Rassy E, Bakouny Z, Choueiri TK, Van Allen EM, Fizazi K, Greco FA, Pavlidis N.

Eur J Cancer. 2020 Mar;127:118-122. doi: 10.1016/j.ejca.2019.12.016. Epub 2020 Jan 30.

PMID:
32007711
8.

Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC.

Clin Genitourin Cancer. 2019 Dec 13. pii: S1558-7673(19)30380-5. doi: 10.1016/j.clgc.2019.12.007. [Epub ahead of print]

PMID:
31926879
9.

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK.

Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27.

10.

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.

Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M.

Cancer Sci. 2020 Mar;111(3):907-923. doi: 10.1111/cas.14294. Epub 2020 Feb 5.

11.

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.

Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Br J Cancer. 2020 Feb;122(4):555-563. doi: 10.1038/s41416-019-0686-0. Epub 2019 Dec 20.

PMID:
31857723
12.

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.

Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G.

Genet Med. 2020 Apr;22(4):709-718. doi: 10.1038/s41436-019-0720-x. Epub 2019 Dec 17.

13.

Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.

Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC.

Eur Urol Oncol. 2019 Nov 27. pii: S2588-9311(19)30160-9. doi: 10.1016/j.euo.2019.11.001. [Epub ahead of print]

PMID:
31786162
14.

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.

Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD.

Prostate Cancer Prostatic Dis. 2019 Nov 29. doi: 10.1038/s41391-019-0189-3. [Epub ahead of print]

PMID:
31784699
15.

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, Choueiri TK, Uzzo R, Apolo AB.

JAMA Oncol. 2019 Nov 21. doi: 10.1001/jamaoncol.2019.4117. [Epub ahead of print]

PMID:
31750870
16.

The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.

DiNatale RG, Xie W, Becerra MF, Silagy AW, Attalla K, Sanchez A, Mano R, Marcon J, Blum KA, Benfante NE, Voss MH, Motzer RJ, Coleman J, Choueiri TK, Reznik E, Russo P, Heng DYC, Hakimi AA.

Eur Urol Oncol. 2020 Feb;3(1):47-56. doi: 10.1016/j.euo.2019.10.002. Epub 2019 Nov 14.

PMID:
31735646
17.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

18.

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.

McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, Choueiri TK.

J Clin Oncol. 2020 Jan 1;38(1):63-70. doi: 10.1200/JCO.19.01882. Epub 2019 Nov 13.

PMID:
31721643
19.

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.

Krimphove MJ, Tully KH, Friedlander DF, Marchese M, Ravi P, Lipsitz SR, Kilbridge KL, Kibel AS, Kluth LA, Ott PA, Choueiri TK, Trinh QD.

J Immunother Cancer. 2019 Nov 7;7(1):289. doi: 10.1186/s40425-019-0782-y.

20.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA; CGC, Hammond LJ, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. doi: 10.6004/jnccn.2019.0054.

PMID:
31693980
21.

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Nassar AH, Hamieh L, Gray KP, Thorner AR, Fay AP, Lasseter KD, Abou Alaiwi S, Nuzzo PV, Flippot R, Krajewski KM, Signoretti S, Choueiri TK, Kwiatkowski DJ.

Mol Cancer Ther. 2020 Feb;19(2):690-696. doi: 10.1158/1535-7163.MCT-19-0642. Epub 2019 Oct 25.

PMID:
31653662
22.

The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma.

McKay RR, Vu P, Albiges LK, Lin X, Simantov R, Temel JS, Choueiri TK.

Clin Genitourin Cancer. 2019 Dec;17(6):443-450.e1. doi: 10.1016/j.clgc.2019.07.004. Epub 2019 Jul 19.

PMID:
31601515
23.

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Paul Nathan, Porta C, Grünwald V, Dezzani L, Han J, Tannir NM.

Clin Genitourin Cancer. 2019 Dec;17(6):425-435.e4. doi: 10.1016/j.clgc.2019.01.015. Epub 2019 Feb 6.

24.

Response of Primary Renal Cell Carcinoma to Systemic Therapy.

Bossé D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, Choueiri TK, McKay RR.

Eur Urol. 2019 Dec;76(6):852-860. doi: 10.1016/j.eururo.2019.08.035. Epub 2019 Oct 6.

PMID:
31594707
25.

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.

Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK.

Eur Urol Oncol. 2019 Sep 24. pii: S2588-9311(19)30142-7. doi: 10.1016/j.euo.2019.09.001. [Epub ahead of print]

PMID:
31562048
26.

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.

Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M.

Nat Commun. 2019 Sep 25;10(1):4346. doi: 10.1038/s41467-019-12361-9.

27.

Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers.

Cole AP, Lu C, Krimphove MJ, Szymaniak J, Sun M, Fletcher SA, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Haider AH, Trinh QD.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1049-1058. doi: 10.6004/jnccn.2019.7296.

PMID:
31487683
28.

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.

Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.3158. [Epub ahead of print] No abstract available.

PMID:
31486842
29.

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC.

Eur Urol. 2019 Dec;76(6):861-867. doi: 10.1016/j.eururo.2019.07.048. Epub 2019 Aug 22.

PMID:
31445844
30.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

31.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
32.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Nov;2(6):643-648. doi: 10.1016/j.euo.2019.03.007. Epub 2019 Apr 5.

PMID:
31411994
33.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK.

Oncologist. 2019 Nov;24(11):1497-1501. doi: 10.1634/theoncologist.2019-0316. Epub 2019 Aug 9.

34.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91. Review.

PMID:
31390169
35.

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S.

Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.

PMID:
31371341
36.

Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals.

Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR, Nabi J, Sammon JD, Choueiri TK, Kibel AS, Sun M, Chang S, Trinh QD.

JNCI Cancer Spectr. 2019 Feb 1;3(1):pkz003. doi: 10.1093/jncics/pkz003. eCollection 2019 Mar.

37.

Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer.

Tan WS, Krimphove MJ, Cole AP, Marchese M, Berg S, Lipsitz SR, Löppenberg B, Nabi J, Abdollah F, Choueiri TK, Kibel AS, Sooriakumaran P, Trinh QD.

Clin Genitourin Cancer. 2019 Oct;17(5):e1060-e1068. doi: 10.1016/j.clgc.2019.06.008. Epub 2019 Jun 19.

PMID:
31303561
38.

Contemporary national trends in prostate cancer risk profile at diagnosis.

Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, Trinh QD, Kibel AS.

Prostate Cancer Prostatic Dis. 2020 Mar;23(1):81-87. doi: 10.1038/s41391-019-0157-y. Epub 2019 Jun 24.

PMID:
31235801
39.

Sex specific associations in genome wide association analysis of renal cell carcinoma.

Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Świątkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, Choueiri TK, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G.

Eur J Hum Genet. 2019 Oct;27(10):1589-1598. doi: 10.1038/s41431-019-0455-9. Epub 2019 Jun 23.

40.

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29.

PMID:
31142504
41.

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.

Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, Choueiri TK, Abdollah F.

Eur Urol Oncol. 2018 May;1(1):83-90. doi: 10.1016/j.euo.2018.03.001. Epub 2018 May 15.

PMID:
31100232
42.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
43.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.

44.

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC.

Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.

45.

Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?

Cole AP, Krasnova A, Ramaswamy A, Friedlander DF, Fletcher SA, Sun M, Choueiri TK, Weissman JS, Kibel AS, Trinh QD.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):593-599. doi: 10.1038/s41391-019-0138-1. Epub 2019 Apr 12.

PMID:
30980025
46.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
47.

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.

Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL.

Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9.

48.

State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.

Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK.

Eur Urol Focus. 2020 Jan 15;6(1):37-40. doi: 10.1016/j.euf.2019.02.014. Epub 2019 Feb 28. Review.

PMID:
30827939
49.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

50.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

Supplemental Content

Loading ...
Support Center